FINWIRES · TerminalLIVE
FINWIRES

HKG:2171

3 stories mentioning HKG:2171Updated 32d ago

Every FINWIRES story that references HKG:2171, newest first.

Asia

Hong Kong Stocks Slide as Trump-Xi Talks Leave Investors Unimpressed; CARsgen Therapeutics Falls

Hong Kong stocks tumbled Friday after U.S. President Donald Trump departed China, with investors left underwhelmed by the outcome of his talks with Chinese President Xi Jinping in Beijing.The Hang Seng Index fell 1.6%, or 426.31 points, to close at 25,962.73, while the Hang Seng China Enterprises Index dropped 1.9%, or 167.60 points, to finish at 8,691.03.A brief U.S. summary of Thursday's talks highlighted what the White House described as a mutual commitment to reopening the Strait of Hormuz amid the conflict involving Iran.There were no signs of progress on potential sales of Nvidia's advanced H200 artificial intelligence chips to China.Trump also told Fox News that Beijing intends to purchase 200 Boeing aircraft, marking its first order for U.S.-made commercial jets in nearly a decade.Reuters reported, however, that the deal fell short of market expectations for about 500 planes.In corporate news, CARsgen Therapeutics (HKG:2171) closed over 10% lower after launching a top-up placement expected to raise about HK$462 million in net proceeds.VPower Group (HKG:1608) fell 17% after its proposed offshore debt restructuring lapsed after failing to become effective by the longstop date.

Hang SengHKG:1608HKG:2171
Asia

CARsgen Therapeutics to Raise HK$462 Million via Top-Up Placement

CARsgen Therapeutics (HKG:2171) is set to raise about HK$462 million in net proceeds through a top-up placement, according to a Friday Hong Kong bourse filing.YIJIE Biotech Holding, a substantial shareholder, is selling 23.7 million existing shares to independent investors.In turn, the company will issue the same number of new shares to YIJIE Biotech at the same price under its general mandate.The placing price is set at HK$19.84 per share, representing a 9.5% discount to the last close and a 12.9% discount to the five-day average.Net proceeds will be used for global clinical development of innovative drugs, equipment, and facility expenses for research and manufacturing, and working capital and general corporate purposes, the filing said.

HKG:2171
Asia

CARsgen Therapeutics' 2025 Loss Narrows Amid Higher Revenue

CARsgen Therapeutics (HKG:2171) booked 97.9 million yuan in attributable loss for 2025, narrowing from a loss of 798.1 million yuan in 2024, according to a Hong Kong bourse filing Friday.Shares of the cell therapy developer gained over 2% in morning trade Monday.Loss per share was 0.18 yuan, compared with 1.44 yuan in the prior year.Revenue rose to 125.7 million yuan from 39.4 million yuan in 2024, figures showed.

HKG:2171

Track with the FINWIRES app suite